Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Exelixis Inc EXEL

Healthcare Biotechnology
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved... see more

Recent & Breaking News (NDAQ:EXEL)

Exelixis, Inc. Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc.

Business Wire July 23, 2023

Exelixis to Release Second Quarter 2023 Financial Results on Tuesday, August 1, 2023

Business Wire July 18, 2023

Farallon Capital Management Comments on Election of All Three of Its Nominees to Exelixis' Board

Business Wire May 31, 2023

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in June

Business Wire May 30, 2023

Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update

Business Wire May 9, 2023

Farallon Capital Management Comments on Successful Campaign for Change at Exelixis

Business Wire May 7, 2023

Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors

Business Wire May 7, 2023

Exelixis to Present at the BofA Securities 2023 Healthcare Conference on May 10, 2023

Business Wire May 3, 2023

Farallon Capital Urges Exelixis Shareholders to Support Change by Electing Its Three Highly Qualified Director Candidates

Business Wire May 3, 2023

Exelixis Files Definitive Proxy Statement and Mails Letter to Shareholders

Business Wire May 1, 2023

Exelixis to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023

Business Wire April 25, 2023

Exelixis Advances Board Refreshment Plan

Business Wire April 13, 2023

Exelixis Reiterates Commitment to Shareholder Value Creation

Business Wire April 5, 2023

Farallon Issues Letter to Exelixis Board of Directors Outlining Case for Change

Business Wire April 5, 2023

Exelixis Announces $550 Million Share Repurchase Program

Business Wire March 20, 2023

Exelixis to Webcast Fireside Chat at the 2023 Guggenheim Healthy Altitudes Summit

Business Wire March 13, 2023

Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer

Business Wire March 2, 2023

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March

Business Wire February 28, 2023

Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

Business Wire February 13, 2023

Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors

Business Wire February 13, 2023